This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Incyte Corporation (Nasdaq: INCY) announced today that several analyses from clinical studies of Jakafi® (ruxolitinib) will be presented at the 2012 American Society of Hematology (ASH) Annual Meeting from Dec. 8 to 11 at the Georgia World Congress Center in Atlanta. Jakafi, an oral Janus kinase (JAK) inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF).
The following abstracts, which are related to the use of Jakafi in patients with MF, will be oral presentations (dates, times and locations of the presentations are included):
Talpaz, M, et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 109/L): A comparison to patients with normal or high starting platelet counts.
Verstovsek, S, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: Durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I.
McMullin, M, et al. The use of erythropoietic-stimulating agents with ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
Barosi, G, et al. An individual patient supply program for ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
Verstovsek, S, et al. Long-term efficacy and safety results from a Phase II study of ruxolitinib in patients with polycythemia vera.
Location: B213-B214, Level 2, Building B
About the Webcast
Incyte will host an investor meeting to discuss the new Jakafi data being presented at ASH. The presentation will be webcast live at 8:45 p.m. EST on December 10, 2012, and can be accessed at
www.incyte.com under Investor Relations, Events and Webcasts. A replay of the event will be available for 60 days.
Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.